BISPECIFIC ANTIBODIES TO Vβ17/CD123 Russian patent published in 2024 - IPC A61K39/395 C07K16/28 A61P35/02 

FIELD: biotechnology.

SUBSTANCE: disclosed are: an isolated anti-Vβ17/CD123 bispecific antibody or an antigen-binding fragment thereof, an isolated nucleic acid encoding HC1 and LC1 of the anti-Vβ17/CD123 bispecific antibody, recovered nucleic acid encoding HC2 and LC2 of the bispecific anti-Vβ17/CD123 antibody, a vector containing the recovered nucleic acid, and a host cell containing it. Also disclosed are: a buffer composition containing an isolated bispecific anti-Vβ17/CD123 antibody or an antigen-binding fragment thereof, method of directing a Vβ17 expressing CD8+ or CD4+ T cell to a cancer cell, involving bringing a Vβ17 expressing CD8+ or CD4+ T cell into contact with a bispecific anti-Vβ17/CD123 antibody or an antigen-binding fragment thereof and a method of inhibiting growth or proliferation of cancer cells, involving bringing cancer cells into contact with a bispecific anti-Vβ17/CD123 antibody or an antigen-binding fragment thereof, and a kit.

EFFECT: invention is used to inhibit growth or proliferation of cancer cells.

15 cl, 13 dwg, 17 tbl, 3 ex